Improving direct patient access to clinical trials
Discover how the healthcare industry can empower patients with the resources and knowledge to access relevant clinical trials and make informed decisions about participation.
Our team consists of incredibly talented writers who occasionally like to share their thinking and expertise. Find out more in our articles below.
Discover how the healthcare industry can empower patients with the resources and knowledge to access relevant clinical trials and make informed decisions about participation.
Today’s medical education ensures practitioners deliver high-quality, evidence-based care. But are healthcare professionals equipped with valuable content and resources to foster collaborative patient-focused discussions driven by trust and mutual respect?
Patient engagement is transforming healthcare, but what drives individuals to take an active role in their care?
Despite the rapid advancements in healthcare research, critical gaps in knowledge remain—especially in rare diseases. How can we identify and address these gaps to drive meaningful progress?
How do clinical trial exit interviews shape patient-centric research, and should they be standard practice?
Discover how patient advocacy groups (PAGs) are transforming rare disease research by bridging the gap between patients, caregivers, and the pharmaceutical industry. Learn more about their mission to improve healthcare outcomes and how the pharmaceutical industry can collaborate to develop life-changing therapies for those most in need.
Discover how patient insight-led drug development ensures patients are at the heart of clinical trial design. Learn how integrating diverse patient feedback can enhance trial accessibility, improve outcomes, and drive true patient-centricity in healthcare.
Patient-reported outcomes (PROs) are crucial in modern healthcare, providing direct insights from patients about their health status, which helps align medical research and development with patient needs.
As the medical industry strives to promote health equity, addressing the lack of diversity in clinical trials has become a key priority. Despite progress, many groups remain underrepresented. This underrepresentation affects the efficacy and safety of treatments for these patients.